NurExone Biologic Valuation
| NRX Stock | 0.63 0.02 3.28% |
NurExone Biologic is overvalued. NurExone Biologic secures a last-minute Real Value of USD0.55 per share. The latest price of the firm is USD0.63. Our model forecasts the value of NurExone Biologic from analyzing the firm fundamentals such as Return On Equity of -2.54, shares owned by insiders of 4.75 %, and Current Valuation of 39.66 M as well as examining its technical indicators and probability of bankruptcy.
Price Book 10.2587 | Enterprise Value 39.7 M | Enterprise Value Ebitda (7.24) |
Overvalued
Today
Please note that NurExone Biologic's price fluctuation is abnormally volatile at this time. Calculation of the real value of NurExone Biologic is based on 3 months time horizon. Increasing NurExone Biologic's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the NurExone stock is determined by what a typical buyer is willing to pay for full or partial control of NurExone Biologic. Since NurExone Biologic is currently traded on the exchange, buyers and sellers on that exchange determine the market value of NurExone Stock. However, NurExone Biologic's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 0.63 | Real 0.55 | Hype 0.61 | Naive 0.68 |
The intrinsic value of NurExone Biologic's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence NurExone Biologic's stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of NurExone Biologic helps investors to forecast how NurExone stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of NurExone Biologic more accurately as focusing exclusively on NurExone Biologic's fundamentals will not take into account other important factors: NurExone Biologic Cash |
|
NurExone Biologic Total Value Analysis
NurExone Biologic is now estimated to have takeover price of 39.66 M with market capitalization of 43.25 M, debt of 1.98 M, and cash on hands of . Please note that takeover price may be misleading and is a subject to mistakes in financial statements. We encourage investors to thoroughly investigate all of the NurExone Biologic fundamentals before making investing decisions based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
39.66 M | 43.25 M | 1.98 M |
NurExone Biologic Asset Utilization
One of the ways to look at asset utilization of NurExone is to check how much profit was generated for every dollar of assets it reports. NurExone Biologic secures a negative usage of assets of -1.14 %, losing USD0.0114 for each dollar of assets held by the firm. Inadequate asset utilization conveys that the company is being less effective with each dollar of assets it secures. Strictly speaking, asset utilization of NurExone Biologic shows how discouraging it operates for each dollar spent on its assets.NurExone Biologic Ownership Allocation
NurExone Biologic maintains a total of 70.89 Million outstanding shares. NurExone Biologic secures 4.75 % of its outstanding shares held by insiders and 0.0 % owned by institutional investors. Please note that no matter how many assets the company has, if the real value of the firm is less than the current market value, you may not be able to make money on it.NurExone Biologic Profitability Analysis
Net Loss for the year was (3.64 M) with loss before overhead, payroll, taxes, and interest of (1.44 M).About NurExone Biologic Valuation
Our relative valuation model uses a comparative analysis of NurExone Biologic. We calculate exposure to NurExone Biologic's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of NurExone Biologic's related companies.Additional Tools for NurExone Stock Analysis
When running NurExone Biologic's price analysis, check to measure NurExone Biologic's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy NurExone Biologic is operating at the current time. Most of NurExone Biologic's value examination focuses on studying past and present price action to predict the probability of NurExone Biologic's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move NurExone Biologic's price. Additionally, you may evaluate how the addition of NurExone Biologic to your portfolios can decrease your overall portfolio volatility.